Atea Narrows Loss To $32.2 Million As Hepatitis C Trial Costs Fall

Cash and investments declined to $191.2 million, while Hercules Capital borrowing supports preparations for a possible U.S. launch.

Share
Atea Narrows Loss To $32.2 Million As Hepatitis C Trial Costs Fall

Atea Pharmaceuticals, which develops oral antiviral treatments for hepatitis, narrowed its third-quarter loss to $32.2 million from $42.0 million a year earlier as hepatitis C trial spending declined, according to Monday’s SEC filing. Cash and investments also fell, and the company added borrowing to help prepare for a potential U.S. launch.

Lower Trial Bills, Smaller Loss

Atea’s unaudited quarterly loss per share narrowed to $0.40 from $0.53. Research and development costs were $27.1 million, versus $38.3 million a year earlier: lower spending on late-stage hepatitis C trials outweighed increased hepatitis E development costs.

Lower stock-based pay also reduced internal research costs and helped bring administrative expenses to $6.9 million from $7.2 million. Interest income and other income declined by $1.8 million as investment balances shrank.

For the first nine months, Atea lost $110.5 million, compared with $113.5 million a year earlier. Its loss per share for that period was $1.38, versus $1.37.

Borrowing For A Possible Launch

Atea held $191.2 million in cash and investments on September 30, down from $301.8 million at December 31, 2025. The company announced a Hercules Capital agreement Monday allowing borrowing of up to $200 million; it drew $65 million when the agreement closed Friday.

Management expects its resources, including that initial borrowing, to cover planned operations into mid-2028. Atea can seek another $135 million, subject to milestones and other loan terms. Management says those additional funds could carry it through profitability if the U.S. launch succeeds and future spending follows its current plan.

The borrowing supports commercial preparations for bemnifosbuvir/ruzasvir, its hepatitis C combination, if approved, along with hepatitis E development. Atea has no products approved for sale.

An Eight-Week Hepatitis C Bet

The hepatitis C program’s pivotal North American result came in July 2026. The combination met the main and secondary goals of its late-stage trial, establishing that it was statistically non-inferior to Epclusa, the sofosbuvir/velpatasvir combination — meaning it met the trial’s standard for comparable efficacy.

Among 905 patients in the main analysis, cure rates were 93.91% for Atea’s regimen and 94.75% for Epclusa. Safety was comparable. Patients without cirrhosis received Atea’s treatment for eight weeks, versus 12 weeks for Epclusa; both regimens used 12 weeks for patients with compensated cirrhosis.

Atea expects results from its overseas late-stage trial in early 2027. That study has enrolled more than 880 patients in 17 countries and is intended to test efficacy across a broad range of hepatitis C variants. Management targets an FDA approval application for mid-2027.

Atea also completed an early-stage study in healthy volunteers that found no drug interaction when its hepatitis C combination was taken with methadone or Suboxone, treatments for opioid use disorder.

Its hepatitis E candidate, AT-587, has completed single-dose testing in healthy volunteers and is undergoing multiple-dose testing. Jean-Pierre Sommadossi, Atea’s CEO and founder, said, “There is a significant unmet need for HEV treatment among people who are immunocompromised and at high risk.”

Atea anticipates starting a hepatitis E proof-of-concept study in the first half of 2027, alongside the expected overseas hepatitis C results and targeted approval application.

Sources

More on Atea Pharmaceuticals

All Atea Pharmaceuticals (AVIR) coverage →